However, when comparing the enrichment levels of the 26 immune signatures between TP53-mutated and TP53-wildtype BCs within the ER+ subtype of BC, we obtained similar results that almost all these immune signatures were more enriched in TP53-mutated ER+ BCs than in TP53-wildtype ER+ BCs (Supplementary Table S13). Here, ESR1 is linked to breast cancer.